Barrett's Esophagus Market Report 2026

The barrett's esophagus market size has grown strongly in recent years. It will grow from $6.71 billion in 2025 to $7.17 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to rising incidence of gastroesophageal reflux disease, increased awareness of esophageal cancer risk, availability of endoscopic diagnostic tools, expansion of gastroenterology specialty care, improved clinical surveillance protocols.

The barrett's esophagus market size is expected to see strong growth in the next few years. It will grow to $9.52 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing adoption of advanced endoscopic imaging, growing use of precision ablation technologies, rising focus on early intervention strategies, expansion of outpatient endoscopic treatments, increasing research into disease progression prevention. Major trends in the forecast period include increasing adoption of endoscopic surveillance programs, rising use of ablation therapies, growing focus on early dysplasia detection, expansion of minimally invasive treatment options, enhanced emphasis on long-term disease monitoring.

The increasing risk of esophageal cancer is expected to drive the growth of the Barrett's esophagus market going forward. Esophageal cancer is a type of cancer that affects the esophagus, a long, hollow tube connecting the throat to the stomach. The incidence of esophageal cancer is higher in patients with Barrett's esophagus who have dysplasia. The risk is particularly elevated in individuals with high-grade dysplasia in Barrett's esophagus. For example, in 2023, according to the American Cancer Society, a US-based organization dedicated to patient support, research, and advocacy for cancer care, esophageal cancer is projected to affect approximately 21,560 people, compared to 20,640 in 2022. Thus, the rising risk of esophageal cancer is contributing to the growth of the Barrett's esophagus market.

Major companies in the Barrett esophagus market are concentrating on developing innovative solutions, such as advanced wireless reflux diagnostic systems, to address the growing need for more accurate, patient-friendly, and long-duration monitoring technologies. Wireless pH-capsule testing systems enable extended reflux monitoring without the discomfort associated with traditional catheter-based methods, providing better patient compliance and more reliable diagnostic data for conditions like GERD that can lead to Barrett esophagus. For example, in April 2023, Laborie Medical Technologies, a US-based medical technology company, introduced the new alpHaONE wireless pH-capsule reflux testing diagnostic system for diagnosing gastroesophageal reflux disease (GERD). The system allows monitoring for up to 96 hours and features a compact design with larger buttons and a fail-safe capsule delivery method. It also includes a software application with a virtual instruction program and user-customizable symptom buttons.

In January 2023, ProPhase Labs, Inc., a U.S.-based diagnostics, genomics, and biotech company, acquired the rights to the BE Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics, Inc., for an undisclosed amount. Through this acquisition, ProPhase aims to commercialize a molecular diagnostic tool for the early detection of esophageal cancer in patients with Barrett’s esophagus, allowing for risk stratification and potentially reducing unnecessary endoscopies. Stella Diagnostics is a U.S.-based molecular diagnostics company that develops first-line diagnostic tools for serious esophageal diseases.

Major companies operating in the barrett's esophagus market are F. Hoffmann-La Roche Ltd., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Medtronic PLC, Merck KGaA, Boston Scientific Corporation, Olympus Corporation, Eisai Co. Ltd., Steris plc, Aurobindo Pharma Limited, Cook Medical Inc., Endo International plc, Sun Pharmaceutical Industries Limited, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Phathom Pharmaceuticals Inc., EndoGastric Solutions Inc., NinePoint Medical Inc., Mederi Therapeutics Inc., Zydus Group, Johnson & Johnson Private Limited.

North America was the largest region in the barrett esophagus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the barrett's esophagus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the barrett's esophagus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the barrett’s esophagus market by increasing costs of imported endoscopic equipment, ablation devices, imaging systems, and pharmaceutical inputs used in diagnosis and treatment. Gastroenterology centers in North America and Europe are most affected due to reliance on imported medical devices, while Asia-Pacific faces cost pressures in equipment procurement. These tariffs are raising procedure costs and slowing technology upgrades. However, they are also encouraging domestic manufacturing of endoscopic devices, regional equipment servicing, and localized innovation in cost-effective treatment solutions.

The barrett's esophagus market research report is one of a series of new reports that provides barrett's esophagus market statistics, including barrett's esophagus industry global market size, regional shares, competitors with a barrett's esophagus market share, detailed barrett's esophagus market segments, market trends and opportunities, and any further data you may need to thrive in the barrett's esophagus industry. This barrett's esophagus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Barrett's esophagus is a medical condition in which acid reflux damages the flat pink lining of the esophagus, the tube that connects the mouth to the stomach. This impacts the lining, causing it to thicken and turn red. Barrett's esophagus is more resistant to stomach acid than squamous cells and intestinal cells, suggesting that tissue changes occur to protect the esophagus from acid exposure. This condition is more common in men than in women and in white individuals.

The primary types of Barrett’s esophagus include no dysplasia, low-grade dysplasia, high-grade dysplasia, and others. No dysplasia is characterized by columnar cells, including goblet cells that appear blue and are filled with mucin. Treatment options include medication, endoscopic therapy, surgery, and others, with routes of administration such as oral, parenteral, rectal, and others. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others.

The barrett esophagus market includes revenues earned by entities by providing pathology services, treatment services and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.